A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-12-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of talquetamab in participants with
relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).